Agile Therapeutics, Inc.
AGRXNASDAQHealthcare
$1.51
+$0.05(+3.42%)
Market Cap$10425795
P/E Ratio—
52W High$2.63
52W Low$0.2
Agile Therapeutics, Inc. (AGRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AGRX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $19.59M | $10.88M | $4.10M | $0.75M | $0.00M |
| Cost of Revenue | $8.98M | $6.84M | $10.72M | $0.28M | $0.16M |
| Gross Profit | $10.62M | $4.05M | ($6.62M) | $0.47M | ($0.16M) |
| Gross Margin %(computed) | 54.18% | 37.19% | -161.35% | 62.35% | — |
| Operating Expenses | |||||
| R&D Expenses | $2.23M | $3.25M | $6.25M | $13.50M | $9.86M |
| G&A Expenses | $10.51M | $11.86M | $14.70M | $12.73M | $9.00M |
| Total Operating Expenses | $30.50M | $45.48M | $64.39M | $49.52M | $18.86M |
| Operating Income | ($19.88M) | ($41.43M) | ($71.00M) | ($49.05M) | ($18.86M) |
| Operating Margin %(computed) | -101.49% | -380.69% | — | — | — |
| Interest Income | $0.08M | $0.08M | $0.03M | $0.31M | $0.25M |
| Interest Expense | $1.42M | $3.13M | $3.91M | $3.11M | $0.00M |
| Income Before Tax | ($14.46M) | ($30.09M) | ($74.89M) | ($51.85M) | ($18.61M) |
| Income Tax Expense | $0.00M | ($4.67M) | $1.69M | $0.00M | ($0.16M) |
| Net Income | ($14.46M) | ($25.41M) | ($76.58M) | ($54.69M) | ($18.44M) |
| Net Margin %(computed) | -73.83% | -233.48% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.71 | $-58.79 | $-63115.49 | $-1291.56 | $-746.20 |
| Wtd Avg Shares | 2.16M | 0.43M | 0.00M | 0.04M | 0.02M |
| EBITDA | ($12.66M) | ($25.42M) | ($64.93M) | ($48.47M) | ($18.61M) |
| EBITDA Margin %(computed) | -64.61% | -233.57% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Agile Therapeutics, Inc. data
About Agile Therapeutics, Inc. (AGRX) Income Statement
Agile Therapeutics, Inc. (AGRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, AGRX reported revenue of $0.02B, gross profit of $0.01B (gross margin 54.18%), and net income of ($0.01B) — a net profit margin of -73.83%.
Frequently asked questions
AGRX · 4 questionsAgile Therapeutics, Inc. (AGRX) reported revenue of $0.02B for 2023, up 80.0% year-over-year.
AGRX revenueAGRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09